Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.

Inclusion Criteria: * Is male or female \>= 18 and \<= 70 years of age * Has a documented history of type 2 diabetes mellitus for a minimum of four months prior to the screening visit * Has a documented history of or current presentation with Stage 1 or Stage 2 hypertension and meets one of the following criteria: * Has controlled hypertension (sSBP \<130 mmHg AND sDBP \<80 mmHg) on \>=2 antihypertensive medications NOTE: A combination drug containing two antihypertensive agents represents two antihypertensive medications OR * Has uncontrolled hypertension (sSBP \>=130 and \<=170 mmHg AND/OR sDBP \>=80 and \<=105 mmHg) on one or two antihypertensive medications OR * Has newly diagnosed or previously untreated hypertension (sSBP \>=130 and \<=170 mmHg AND/OR sDBP \>=80 and \<=105 mmHg * At Randomization, sitting systolic blood pressure (sSBP) \>= 130 mmHg or sitting diastolic blood pressure (sDBP) \>= 80 mmHg and sSBP \<= 170 mmHg and sDBP \<= 105 mmHg * Has been on a stable dose of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) for a minimum of four months prior to the screening visit Exclusion Criteria: * Has any clinically significant abnormality identified in the screening physical examination, laboratory tests or electrocardiogram which, in the judgement of the investigator, would preclude safe completion of the study * Is female of childbearing potential * Has any of these cardiac conditions: uncontrollable or symptomatic arrhythmias, unstable angina, sick sinus syndrome or second or third degree heart block (unless treated with a permanent, functioning pacemaker), bradycardia (heart rate \<55 bpm), and stroke within three months of study screening, and history of myocardial infarction. * Has Congestive Heart Failure NYHA (New York Heart Association) class II-IV * Has type 1 diabetes mellitus * Has newly diagnosed type 2 diabetes (within 4 months of screening visit) * Has HbA1c \> 8.5% * Has the following, as it relates to subject's antidiabetic therapy:Initiated or changed dosage or formulation of thiazolidinediones (TZDs) within 6 months of screening visit. * A history of acute or chronic acidosis, including diabetic ketoacidosis * Has current clinical diagnosis of chronic obstructive pulmonary disease (COPD, e.g., chronic bronchitis) or asthma * Has a history of bronchospastic disease not undergoing active therapy in whom, in the investigator's opinion, treatment with study medication could provoke bronchospasm * Has evidence of any of the following clinically significant diseases that could impair the absorption, metabolism, or excretion of orally-administered medication: * renal disease defined as estimated Glomerular Filtration Rate (eGFR) \<60mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula below: GFR (mL/min/1.73m2) = 186 x \[Serum Creatinine (umol/L) x 0.0113\]-1.154 x Age(years)-0.203 (x 0.742 if female) * hepatic disease (i.e., ALT or AST levels greater than three times the upper limit of normal range, history of hepatic impairment, or by clinical assessment) * Chronic biliary disorders * Has endocrine disorders (e.g., pheochromocytoma, active and untreated hypo or hyperthyroidism) * Has any known contraindication to ACE inhibitors, alpha- or beta-blocker treatment * Has systemic disease, including cancer, with reduced (\<12 months) life expectancy * Has used an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication * Has a history of a psychological illness or any condition that would interfere with the subject's ability to understand or complete the requirements of the study